IN2012DN05142A - - Google Patents

Download PDF

Info

Publication number
IN2012DN05142A
IN2012DN05142A IN5142DEN2012A IN2012DN05142A IN 2012DN05142 A IN2012DN05142 A IN 2012DN05142A IN 5142DEN2012 A IN5142DEN2012 A IN 5142DEN2012A IN 2012DN05142 A IN2012DN05142 A IN 2012DN05142A
Authority
IN
India
Prior art keywords
crystalline forms
pentanamide
amino
methyl
present
Prior art date
Application number
Inventor
Rajgopal Munigeti
Frank M Longo
Original Assignee
Pharma Trophix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Trophix Inc filed Critical Pharma Trophix Inc
Publication of IN2012DN05142A publication Critical patent/IN2012DN05142A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention includes crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethy1)- pentanamide and crystalline forms of salts and/or solvates of 2-amino-3-methyl-N-(2- morpholinoethy1)-pentanamide. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic use of the crystalline forms.
IN5142DEN2012 2009-11-12 2010-11-12 IN2012DN05142A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26067109P 2009-11-12 2009-11-12
US29427910P 2010-01-12 2010-01-12
US35079710P 2010-06-02 2010-06-02
PCT/US2010/056537 WO2011060262A1 (en) 2009-11-12 2010-11-12 Crystalline forms of neurotrophin mimetic compounds and their salts

Publications (1)

Publication Number Publication Date
IN2012DN05142A true IN2012DN05142A (en) 2015-10-23

Family

ID=43992064

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5142DEN2012 IN2012DN05142A (en) 2009-11-12 2010-11-12

Country Status (9)

Country Link
US (3) US9271986B2 (en)
EP (2) EP2498782B1 (en)
JP (3) JP5863663B2 (en)
CN (3) CN108383804A (en)
AU (1) AU2010319349B2 (en)
CA (2) CA2780940C (en)
ES (1) ES2712752T3 (en)
IN (1) IN2012DN05142A (en)
WO (1) WO2011060262A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2780940C (en) 2009-11-12 2021-08-31 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
WO2014052659A1 (en) * 2012-09-27 2014-04-03 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
WO2016196804A1 (en) * 2015-06-04 2016-12-08 Balchem Corporation Hydration control for choline salts
US11215532B2 (en) 2020-05-04 2022-01-04 Ford Global Technologies, Llc Methods and systems for exhaust gas recirculation system diagnostics

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3541130A (en) 1967-02-06 1970-11-17 Boehringer Sohn Ingelheim 1-(cyanophenoxy)-2-hydroxy-3-tert.-butylamine propanes
US4613676A (en) * 1983-11-23 1986-09-23 Ciba-Geigy Corporation Substituted 5-amino-4-hydroxyvaleryl derivatives
US4743607A (en) 1987-05-29 1988-05-10 Merrell Dow Pharmaceuticals Inc. Cardiotonic tricyclic imidazolones
EP0413751A4 (en) 1988-05-02 1992-07-22 N. Eric Naftchi Neurologically active compounds
US5028622A (en) 1988-05-06 1991-07-02 Ajinomoto Company, Inc. Administration of amino acids as treatment for neurodegenerative disorders
US5321029A (en) 1988-11-14 1994-06-14 Beecham-Wuelfing Gmbh & Co.K.G. Xanthines
CA2010531A1 (en) * 1989-03-06 1990-09-06 Werner Neidhart Amino acid derivatives
DE59205565D1 (en) 1991-10-07 1996-04-11 Hoechst Ag Carboxylic ester protecting groups, a process for their preparation, their coupling to a functional group and their use
US5608067A (en) 1993-12-09 1997-03-04 Afonso; Adriano 4-substituted pyrazoloquinoline derivatives
GB9402331D0 (en) 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
JPH08119922A (en) 1994-10-21 1996-05-14 Torii Yakuhin Kk o-pivaloyl-tyrosine derivative
WO1996016980A1 (en) 1994-11-29 1996-06-06 Novartis Ag Morpholinoethylamide derivatives
JPH1081661A (en) 1995-10-23 1998-03-31 Sankyo Co Ltd Hydroxamic acid derivative
US5958875A (en) 1996-03-29 1999-09-28 The Regents Of The University Of California Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity
AU719038B2 (en) 1996-03-29 2000-05-04 Trustees Of Boston University Methods for diagnosing and treating Alzheimer's disease
AU2645497A (en) 1996-05-06 1997-11-26 Zeneca Limited Thio derivatives of hydroxamic acids
GB9613547D0 (en) 1996-06-27 1996-08-28 Pharmacia Spa Matrix metalloproteinase inhibitors
GB9616105D0 (en) 1996-07-31 1996-09-11 Univ Kingston TrkA binding site of NGF
GB9715962D0 (en) 1996-08-23 1997-10-01 Zeneca Ltd Sulfonamides
EP0968206B8 (en) 1997-02-19 2007-01-24 Berlex, Inc. N-heterocyclic derivatives as nos inhibitors
FR2762315B1 (en) 1997-04-22 1999-05-28 Logeais Labor Jacques AMINO ACID DERIVATIVES INHIBITOR OF EXTRACELLULAR MATRIX METALLOPROTEASES AND TNF ALPHA RELEASE
WO1998054123A1 (en) 1997-05-30 1998-12-03 Warner-Lambert Company Substituted peptidylamine calcium channel blockers
US6342507B1 (en) 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
US20020022657A1 (en) * 1998-02-11 2002-02-21 Francine Gervais Methods for modulating neuronal cell death
WO1999050264A1 (en) 1998-03-30 1999-10-07 Kyowa Hakko Kogyo Co., Ltd. Quinazoline derivatives
FR2783519B1 (en) 1998-09-23 2003-01-24 Sod Conseils Rech Applic NOVEL AMIDINE DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP2002529404A (en) 1998-11-06 2002-09-10 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング Cystine derivatives as therapeutics for substrate metalloprotease-related diseases
EP1140914A1 (en) 1998-12-18 2001-10-10 Warner-Lambert Company Non-peptide nk1 receptors antagonists
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
US6492380B1 (en) 1999-05-17 2002-12-10 Queen's University At Kingston Method of inhibiting neurotrophin-receptor binding
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
US6858577B1 (en) 1999-06-29 2005-02-22 Ortho-Mcneil Pharmaceutical, Inc. Indole peptidomimetics as thrombin receptor antagonists
DE19939910A1 (en) 1999-08-23 2001-03-01 Morphochem Ag New compounds that inhibit tryptase activity
EP1214293A1 (en) * 1999-09-08 2002-06-19 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
ES2276706T3 (en) 1999-12-08 2007-07-01 Teijin Limited ANTIGONISTS OF THE CCR5 RECEIVER OF CYCLINE AMINES.
DK1265605T3 (en) 2000-01-18 2007-02-12 Univ Mcgill Pharmaceutical compositions comprising peptide mimetic cyclic beta rotation compound
AR028606A1 (en) 2000-05-24 2003-05-14 Smithkline Beecham Corp NEW MMP-2 / MMP-9 INHIBITORS
US6699989B1 (en) 2000-08-28 2004-03-02 B. Vithal Shetty Antiviral and antimicrobial guanidine or biguanidine derivatives
WO2002048660A1 (en) 2000-12-13 2002-06-20 Spelman College Multiplex coherent raman spectroscopy detector and method
RS13004A (en) 2001-07-11 2006-10-27 Elan Pharmaceuticals Inc. N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds
US20040248984A1 (en) 2001-08-29 2004-12-09 Josef Krieglstein Use of $g(b)-adrenoceptor agonists for the treatment of neurodegenerative diseases
AU2002335824A1 (en) * 2001-10-12 2003-04-22 Case Western Reserve University Neuronal regeneration
EA200400648A1 (en) 2001-11-08 2005-04-28 Элан Фармасьютикалз, Инк. N, N'-SUBSTITUTED DERIVATIVES 1,3-DIAMINO-2-HYDROXYPROPANE
CN1662506A (en) * 2002-05-03 2005-08-31 以色列生物研究所 Methods and compositions for treating diseases of the central and peripheral nervous systems and useful new compounds thereof
UA77526C2 (en) 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
AU2003299084B2 (en) 2002-09-25 2009-03-26 Georgia Tech Research Corporation Ketoamide inhibitors in chronic nerve disease
US20040077635A1 (en) 2002-10-02 2004-04-22 Qiao Jennifer X. Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor Xa inhibitors
US20040186044A1 (en) 2002-11-06 2004-09-23 Cosgaya Jose Miguel Modulation of myelination by interaction with P75 and TRK receptors
US20040167183A1 (en) 2003-02-20 2004-08-26 The Procter & Gamble Company Phenethylamino sulfamic acids
GB0304433D0 (en) 2003-02-27 2003-04-02 Xceleron Ltd Improvements relating to chemical libraries
US7202269B2 (en) 2003-10-30 2007-04-10 Janssen Pharmaceutica N.V. GlyT2 modulators
CA2547283C (en) 2003-11-26 2010-11-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
JP2007522129A (en) * 2004-01-21 2007-08-09 エラン ファーマシューティカルズ，インコーポレイテッド Methods for treating amyloidosis using aspartic protease inhibitors
JP4775259B2 (en) 2004-03-31 2011-09-21 味の素株式会社 Aniline derivative
CA2573378A1 (en) 2004-07-12 2006-01-19 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide derivatives as inhibitors of histone deacetylase
JP4194540B2 (en) 2004-07-27 2008-12-10 キヤノン株式会社 Image forming apparatus
EP1871420A4 (en) 2005-04-15 2010-09-22 Univ North Carolina METHOD FOR FACILITATING CELL SURVIVAL USING NEUROTROPHIN MIMETICS
US20110230479A1 (en) 2005-04-15 2011-09-22 Longo Frank M Neurotrophin mimetics and uses thereof
US8686045B2 (en) 2005-06-08 2014-04-01 The University Of North Carolina At Chapel Hill Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
ES2436225T3 (en) 2005-12-22 2013-12-27 Hydra Biosciences, Inc. TRPA1 inhibitors for pain treatment
WO2008107365A1 (en) * 2007-03-02 2008-09-12 Medivir Ab New compounds
EP2403839A4 (en) 2009-03-06 2014-05-28 Univ North Carolina MIMETICS OF NEUROTROPHIN AND USES THEREOF
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
CA2780940C (en) 2009-11-12 2021-08-31 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US20120322799A1 (en) 2009-11-30 2012-12-20 Pharmatrophix, Inc. Deuterated compounds useful for treating neurodegenerative diseases
WO2014052659A1 (en) 2012-09-27 2014-04-03 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts

Also Published As

Publication number Publication date
EP3470402A1 (en) 2019-04-17
US20180037559A1 (en) 2018-02-08
EP2498782B1 (en) 2019-01-09
CN104761515A (en) 2015-07-08
CA2780940A1 (en) 2011-05-19
EP3470402B1 (en) 2021-01-06
US9271986B2 (en) 2016-03-01
JP2016020380A (en) 2016-02-04
JP2013510874A (en) 2013-03-28
CN104761515B (en) 2018-03-09
CA3125909C (en) 2023-10-31
CN108383804A (en) 2018-08-10
JP2018115218A (en) 2018-07-26
AU2010319349A1 (en) 2012-07-05
JP5863663B2 (en) 2016-02-16
JP6657294B2 (en) 2020-03-04
HK1212970A1 (en) 2016-06-24
AU2010319349B2 (en) 2015-07-16
EP2498782A1 (en) 2012-09-19
EP2498782A4 (en) 2014-03-12
CA2780940C (en) 2021-08-31
ES2712752T3 (en) 2019-05-14
US20160176832A1 (en) 2016-06-23
CN102740856B (en) 2015-02-18
WO2011060262A1 (en) 2011-05-19
US10532988B2 (en) 2020-01-14
US20130005731A1 (en) 2013-01-03
CA3125909A1 (en) 2011-05-19
CN102740856A (en) 2012-10-17

Similar Documents

Publication Publication Date Title
MY181898A (en) Heterocyclic compounds and uses thereof
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
MX338489B (en) Hydantoin derivatives useful as kv3 inhibitors.
TN2011000673A1 (en) Bace inhibitors
MX2011007930A (en) Crystalline insulin-conjugates.
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
MX2009008347A (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use.
MX2012004114A (en) Heterocyclic compounds useful as pdk1 inhibitors.
TR201813877T4 (en) COMPOUNDS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY.
MX2012007098A (en) Phenol derivatives and pharmaceutical or cosmetic use thereof.
MX2012007161A (en) Phenol derivatives and pharmaceutical or cosmetic use thereof.
JO2892B1 (en) Inhibitors of cyp 17
MX2009008430A (en) Anti-robo4 antibodies and uses therefor.
UA104885C2 (en) Isothiazolyloxyphenyl amidines and use thereof as fungicides
TW201713640A (en) Bruton's tyrosine kinase inhibitors
WO2011032169A3 (en) Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
PH12013500065A1 (en) Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
MX2012004780A (en) Akt inhibitors.
JO3755B1 (en) Testosterone formulations
MX2013002851A (en) Inhibitors of notum pectinacetylesterase and methods of their use.
MX2011012533A (en) Spiro epoxides as intermediates.
IN2012DN05142A (en)
MX2009013500A (en) Novel herbicides.
MX2010001303A (en) Therapeutic compounds.